Combination therapy with methotrexate in inflammatory bowel disease: Time to COMMIT?

Gastroenterology

Volumn 146, Issue 3, 2014, Pages 608-611

  Narula, Neeraj ^a   Peyrin Biroulet, Laurent ^b   Colombel, Jean Frederic ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITÉ DE LORRAINE   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; STEROID;

ANTIBODY PRODUCTION; CANCER RISK; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; LYMPHOMA; MONOTHERAPY; OUTCOME ASSESSMENT; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SKIN CANCER; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; MALE; METHOTREXATE;

EID: 84894313686     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.01.040     Document Type: Editorial

References (14)

1. J. Colombel, W. Sandborn, and W. Reinish et al. Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
2. B.G. Feagan, J.W.D. McDonald, and R. Panaccione et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease Gastroenterology 146 2014 681 688
3. B. Feagan, J. Rochon, and R. Fedorak et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators N Engl J Med 332 1995 292 297
4. B. Feagan, R. Fedorak, and E. Irvine et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 342 2000 1627 1632
5. F. Breedveld, M. Weisman, and A. Kavanaugh et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 2006 26 37
6. J. Smolen, D. Van Der Heijde, and E. St Clair et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial Arthritis Rheum 54 2006 702 710
7. D. Laharie, J. Seneschal, and T. Schaeverbeke et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study J Hepatol 53 2010 1035 1040
8. B. Cohen, J. Torres, and J. Colombel Immunosuppression in inflammatory bowel disease: how much is too much? Curr Opin Gastroenterol 28 2012 341 348
9. M. Lémann, J. Mary, and B. Duclos et al. Infliximab plus azathioprine for steroid dependent Crohn's disease patients: a randomized placebo-controlled trial Gastroenterology 130 2006 1054 1061
10. H. Sokol, P. Seksik, and F. Carrat et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy Gut 59 2010 1363 1368
11. D. Laharie, A. Reffet, and G. Belleannee et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab Aliment Pharmacol Ther 33 2011 714 721
12. S. Vermeire, M. Noman, and G. Van Assche et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease Gut 56 2007 1226 1231
13. Carbonnel F, et al. Comparison of Methotrexate vs Placebo in Steroid-Refractory Ulcerative Colitis (METEOR). Clinicaltrials.gov identifier: NCT00498589 2008.
14. Herfarth H, et al. Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (Merit-UC). Clinicaltrials.gov identifier: NCT01393405 2013.